Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Folic acid + 5-Fluorouracil + Irinotecan + Oxaliplatin
FOLFIRINOX
Routinely available
Local application
29/03/2023
Indication
As adjuvant treatment following potentially curative resection of pancreatic cancer.
Therapeutic Area
Malignant disease and immunosuppression
Status Description
Routinely available in line with local guidance for prescribing
Formulation
Modified FOLFIRINOX regimen
Comments
-